| Ticker Details |
Altimmune, Inc.
Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases.
|
| IPO Date: |
May 22, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$604.95M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.33 | 4.67%
|
| Avg Daily Range (30 D): |
$0.08 | 2.55%
|
| Avg Daily Range (90 D): |
$0.08 | 2.62%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.07M |
| Avg Daily Volume (30 D): |
4.1M |
| Avg Daily Volume (90 D): |
3.88M |
| Trade Size |
| Avg Trade Size (Sh.): |
170 |
| Avg Trade Size (Sh.) (30 D): |
228 |
| Avg Trade Size (Sh.) (90 D): |
226 |
| Institutional Trades |
| Total Institutional Trades: |
1,708 |
| Avg Institutional Trade: |
$1.68M |
| Avg Institutional Trade (30 D): |
$1.04M |
| Avg Institutional Trade (90 D): |
$1.46M |
| Avg Institutional Trade Volume: |
.22M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.87M |
| Avg Closing Trade (30 D): |
$1.15M |
| Avg Closing Trade (90 D): |
$1.57M |
| Avg Closing Volume: |
259.17K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-.12
|
$-.18
|
$-.26
|
|
Diluted EPS
|
$-.12
|
$-.18
|
$-.26
|
|
Revenue
|
$M
|
$M
|
$.03M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-22.83M
|
$-22.56M
|
$-27.36M
|
|
Operating Income / Loss
|
$-26.23M
|
$-24.24M
|
$-28.89M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-34.59M
|
$53.84M
|
$-17.48M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 14, 2018
|
1:30
|
|
May 05, 2017
|
1:10
|
|
May 04, 2017
|
1:10
|
|
Jul 25, 2007
|
1:50
|
|
|
|
